Harmony Biosciences Holdings Inc
HRMY32.980USD
+1.160+3.65%
收盘 11/11, 16:00（美东）报价延迟15分钟
1.90B总市值
10.23市盈率 TTM
关于 Harmony Biosciences Holdings Inc 公司
Harmony Biosciences Holdings, Inc. 是一家商业阶段的制药公司。该公司专注于开发和商业化治疗罕见神经系统疾病患者以及医疗需求未得到满足的其他神经系统疾病患者的疗法。其产品 WAKIX (pitolisant) 是一种首创分子，具有新颖的作用机制，旨在通过与 H3 受体结合来增强大脑中的组胺信号传导。其 WAKIX 被开发用于治疗成人发作性睡病患者的过度日间嗜睡 (EDS) 和治疗成人发作性睡病患者的猝倒症。该公司还提供研究化合物 HBS-102，这是一种黑色素浓缩激素受体 1 (MCHR1) 拮抗剂，靶向大脑中的 MCH 神经元。该公司还开发了 ZYN002，一种制药制造的合成大麻二酚。该公司还专注于扩大中枢神经系统资产后期管线中的罕见癫痫治疗领域：EPX-100 和 EPX-200。
Harmony Biosciences Holdings Inc简介
公司代码HRMY
公司名称Harmony Biosciences Holdings Inc
上市日期Aug 19, 2020
CEODr. Jeffrey M. (Jeff) Dayno, M.D.
员工数量- -
证券类型Ordinary Share
年结日Aug 19
公司地址630 W Germantown Pike
城市PLYMOUTH MEETING
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编19462
电话14845399800
网址https://www.harmonybiosciences.com/
公司代码HRMY
上市日期Aug 19, 2020
CEODr. Jeffrey M. (Jeff) Dayno, M.D.
Harmony Biosciences Holdings Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Jeffrey S. (Jeff) Aronin
Mr. Jeffrey S. (Jeff) Aronin
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
251.92K
--
Dr. Kumar Budur, M.D.
Dr. Kumar Budur, M.D.
Executive Vice President and Chief Medical and Scientific Officer
Executive Vice President and Chief Medical and Scientific Officer
10.89K
+983.18%
Mr. Andrew Serafin, J.D.
Mr. Andrew Serafin, J.D.
Chief Strategy Officer
Chief Strategy Officer
1.64K
--
Mr. Adam Zaeske
Mr. Adam Zaeske
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Ron Philip
Mr. Ron Philip
Independent Director
Independent Director
--
--
Dr. Andreas Wicki, Ph.D.
Dr. Andreas Wicki, Ph.D.
Independent Director
Independent Director
--
--
Mr. R. Mark Graf
Mr. R. Mark Graf
Independent Director
Independent Director
--
--
Mr. Gary L. Sender
Mr. Gary L. Sender
Independent Director
Independent Director
--
--
Dr. Jeffrey M. (Jeff) Dayno, M.D.
Dr. Jeffrey M. (Jeff) Dayno, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter Anastasiou
Mr. Peter Anastasiou
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Jeffrey S. (Jeff) Aronin
Mr. Jeffrey S. (Jeff) Aronin
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
251.92K
--
Dr. Kumar Budur, M.D.
Dr. Kumar Budur, M.D.
Executive Vice President and Chief Medical and Scientific Officer
Executive Vice President and Chief Medical and Scientific Officer
10.89K
+983.18%
Mr. Andrew Serafin, J.D.
Mr. Andrew Serafin, J.D.
Chief Strategy Officer
Chief Strategy Officer
1.64K
--
Mr. Adam Zaeske
Mr. Adam Zaeske
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Ron Philip
Mr. Ron Philip
Independent Director
Independent Director
--
--
Dr. Andreas Wicki, Ph.D.
Dr. Andreas Wicki, Ph.D.
Independent Director
Independent Director
--
--
收入明细
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2022
暂无数据
地区USD
名称
营收
占比
United States
200.49M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 9月5日 周五
更新时间: 9月5日 周五
持股股东
股东类型
持股股东
持股股东
占比
Marshman Fund Trust ii
10.51%
BlackRock Institutional Trust Company, N.A.
10.02%
The Vanguard Group, Inc.
8.83%
Fidelity Management & Research Company LLC
8.14%
HBM Partners AG
3.73%
其他
58.77%
持股股东
持股股东
占比
Marshman Fund Trust ii
10.51%
BlackRock Institutional Trust Company, N.A.
10.02%
The Vanguard Group, Inc.
8.83%
Fidelity Management & Research Company LLC
8.14%
HBM Partners AG
3.73%
其他
58.77%
股东类型
持股股东
占比
Investment Advisor
47.92%
Investment Advisor/Hedge Fund
22.47%
Corporation
10.51%
Hedge Fund
5.41%
Research Firm
4.32%
Pension Fund
1.21%
Private Equity
0.85%
Venture Capital
0.66%
Individual Investor
0.55%
其他
6.11%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
556
48.04M
83.41%
-15.75M
2025Q2
552
60.78M
105.69%
-11.17M
2025Q1
573
60.17M
104.79%
-12.54M
2024Q4
571
62.71M
109.35%
-5.92M
2024Q3
559
64.22M
112.66%
-9.33M
2024Q2
548
64.68M
113.76%
-9.02M
2024Q1
546
63.23M
110.16%
-590.81K
2023Q4
534
62.18M
105.68%
-302.40K
2023Q3
502
63.52M
115.31%
-874.73K
2023Q2
488
66.12M
110.24%
+3.64M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Marshman Fund Trust ii
6.05M
10.52%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.77M
10.03%
+154.94K
+2.76%
Jun 30, 2025
The Vanguard Group, Inc.
5.10M
8.87%
+412.76K
+8.80%
Jun 30, 2025
Fidelity Management & Research Company LLC
4.69M
8.15%
-654.33K
-12.25%
Jun 30, 2025
HBM Partners AG
2.15M
3.73%
--
--
Mar 17, 2025
State Street Investment Management (US)
1.63M
2.83%
+50.21K
+3.18%
Jun 30, 2025
LSV Asset Management
1.49M
2.59%
+293.54K
+24.56%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.58M
2.75%
+357.38K
+29.18%
Jun 30, 2025
American Century Investment Management, Inc.
1.50M
2.61%
+212.63K
+16.50%
Jun 30, 2025
Marshall Wace LLP
1.21M
2.1%
+321.95K
+36.27%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月2日 周日
更新时间: 11月2日 周日
机构名称
占比
LSV Disciplined Value ETF
30.68%
Invesco Pharmaceuticals ETF
2.01%
SPDR S&P Pharmaceuticals ETF
1.99%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.5%
Virtus LifeSci Biotech Products ETF
1.38%
Invesco S&P SmallCap 600 GARP ETF
1.13%
Euclidean Fundamental Value ETF
1.11%
VictoryShares Small Cap Free Cash Flow ETF
0.91%
ETC 6 Meridian Small Cap Equity ETF
0.86%
Acquirers Small and Micro Deep Value ETF
0.81%
查看更多
LSV Disciplined Value ETF
占比30.68%
Invesco Pharmaceuticals ETF
占比2.01%
SPDR S&P Pharmaceuticals ETF
占比1.99%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比1.5%
Virtus LifeSci Biotech Products ETF
占比1.38%
Invesco S&P SmallCap 600 GARP ETF
占比1.13%
Euclidean Fundamental Value ETF
占比1.11%
VictoryShares Small Cap Free Cash Flow ETF
占比0.91%
ETC 6 Meridian Small Cap Equity ETF
占比0.86%
Acquirers Small and Micro Deep Value ETF
占比0.81%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
